|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM352351535 |
| 003 |
DE-627 |
| 005 |
20231226053527.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109247
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1174.xml
|
| 035 |
|
|
|a (DE-627)NLM352351535
|
| 035 |
|
|
|a (NLM)36724835
|
| 035 |
|
|
|a (PII)S1521-6616(23)00026-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Jiaqi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.02.2023
|
| 500 |
|
|
|a Date Revised 18.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a PURPOSE: To describe the effectiveness and tolerability of low-dose interleukin (IL)-2 in treating patients with chronic spontaneous urticaria (CSU) refractory to H1-antihistamines
|
| 520 |
|
|
|a METHODS: This retrospective study included CSU patients who received treatment with at least one cycle of IL-2, injected intramuscularly at a dose of 1.0 million international units daily for 7 consecutive days, after failing treatment with H1-antihistamines. Patients were followed up for ≥12 weeks
|
| 520 |
|
|
|a RESULTS: Of the 15 patients, 7 (46.7%) and 11 (73.3%) achieved complete response at Week 2 and Week 12, respectively. The mean change of urticaria control test (UCT) and weekly urticaria activity score (UAS7) from baseline was 6.6 (95% CI, 4.2 to 8.9) and - 16.9 (95% CI, -24.0 to -9.8), respectively, at Week 12. Local injection-site reactions were the most common adverse events. No serious adverse events were reported
|
| 520 |
|
|
|a CONCLUSION: Low-dose IL-2 treatment improves symptoms and disease control for CSU patients refractory to H1-antihistamines
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Autologous serum skin test (ASST)
|
| 650 |
|
4 |
|a Chronic spontaneous urticaria (CSU)
|
| 650 |
|
4 |
|a Interleukin-2 (IL-2)
|
| 650 |
|
4 |
|a Urticaria control test (UCT)
|
| 650 |
|
4 |
|a Weekly urticaria activity score (UAS7)
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Histamine Antagonists
|2 NLM
|
| 700 |
1 |
|
|a He, Liting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yi, Wanyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Qing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tan, Yixin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Guiying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Yuwen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, Rong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Qianjin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Long, Hai
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 247(2023) vom: 01. Feb., Seite 109247
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:247
|g year:2023
|g day:01
|g month:02
|g pages:109247
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109247
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 247
|j 2023
|b 01
|c 02
|h 109247
|